ARTLNasdaqPharmaceutical Preparations

Artelo Biosciences, Inc. (ARTL) earnings date, market-implied expected move, and options open interest by expiry

2.34

+0.17 · +7.83%

post 2.44 +4.27%

After hours16:51 ETdelayed

Open2.15Volume30,484Mkt cap$1.1M

Day2.15 – 2.44100%52-wk2.05 – 179.190%

ARTL

Artelo Biosciences, Inc.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Apr 12

before open · in 160 days

est.Q3 FY26

Calendar

Next report

Last report

—

Largest filed tie

filed ties

13F top-10 QoQ

—

Top fund weight

—

Artelo Biosciences (ARTL) is expected to report on Apr 12 before open (estimated date).

Implied vs realized

No reported quarters.

Implied vs realized

Positioning

No open-interest data.

Positioning

Linked exposure

No linked exposure.

Linked exposure

Revenue flow

No filed income statement.

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 16:45 ET

Intraday

Event sensitivity

PPI ×1.73· ±8.3% vs ±4.8% · 10 releases

eventrelease day|move|up · n×base

PPIproducer prices±8.3%5 of 10×1.73

FOMCrate decision±6.5%6 of 24×1.36

CPIconsumer prices±5.1%3 of 10×1.06

NFPjobs report±4.3%2 of 10×0.88

PCEpersonal income & outlays±3.1%8 of 19×0.64

CPROFcorporate profits±2.8%5 of 12×0.59

GDPgross domestic product±2.8%8 of 19×0.59

Bar = avg |move| to ±9% · tick = ±4.8% avg day · ×base = |move| ÷ ±4.8% · min 6 releases

Earnings history

EPS -0.89 · consensus —

Quarter	Reported	EPS	Consensus
Q2 FY26	—	-0.89	—
Q1 FY26	—	-4.00	—
Q3 FY25	—	-3.97	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod